Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
1998 1
1999 1
2000 3
2001 1
2015 1
2016 1
2018 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: sundarapandiyan k. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ, Vitale L, O'Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T. Thomas LJ, et al. Among authors: sundarapandiyan k. Mol Cancer Ther. 2016 Dec;15(12):2946-2954. doi: 10.1158/1535-7163.MCT-16-0393. Epub 2016 Sep 26. Mol Cancer Ther. 2016. PMID: 27671527
Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.
Graziano RF, Goldstein J, Sundarapandiyan K, Somasundaram C, Keler T, Deo YM. Graziano RF, et al. Among authors: sundarapandiyan k. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):124-7. doi: 10.1007/s002620050413. Cancer Immunol Immunother. 1997. PMID: 9435854 No abstract available.
12 results